2588-P: Enhancing Quality of Life, Reducing Diabetes Distress, and Optimizing Health Care Resource Use through a Digitally Enabled Lifestyle Program Including a Low-Calorie Diet with Diabetes Specific Nutritional Formula and Coaching

Introduction and Objective: The RESET study—Remission of diabEtes through low-calorie diet with diabetes-specific formula and digitally enabled technology—has demonstrated significant improvements in weight loss and overall diabetes management among adults with type 2 diabetes (T2D) and excess body weight. While the primary outcomes focused on metabolic parameters, the study also assessed 12-month changes in health-related quality of life (HRQoL), diabetes-related distress, and healthcare resource utilization—important but less frequently studied outcomes in lifestyle intervention research. Methods: Adult participants completing all phases of the RESET program over 12-months (n=105) completed the SF-12 HRQoL and PAID-5 diabetes distress questionnaires at baseline and 12 months. Healthcare resource use including outpatient, emergency department (ED), and general practitioner (GP) visits prior to and during the program were obtained through participants’ clinical records and self-reports. Within participant changes were assessed using paired t-tests. Results: At 12 months, HRQoL improved significantly, as indicated by a mean SF-12 increase of 0.1 (±0.2, p0.001). The SF-12 mental component score increased by 3.0 (±8.4; p=0.047). Diabetes distress score decreased by 6.2 (±4.4, p0.001) on the PAID-5 scale, with the share of participants showing diabetes distress (PAID-5 ≥8) decreasing from 59% to 8%. The number of outpatient visits declined by one visit on average (p=0.01) and GP visits declined by 1.7 (p=0.006), while number of ED visits were unchanged (p=0.75) Conclusion: A digitally enabled lifestyle program including a low-calorie diet using DSNF with coaching led to significant improvements in HRQoL, lowered diabetes distress, and reduced outpatient and GP visits, supporting potential economic value in diabetes care management. Disclosure K. Kerr: Employee; Current; Abbott. M. Camprubi Robles: Employee; Current; Abbott. L.C. Taylor: Employee; Current; Changing Health Ltd. C. Lumsden: None. S. Leathen: None. R. Rueda: Employee; Current; Abbott. N. Northway: None. S.S. Sulo: Employee; Current; Abbott. Funding Financial support for this study was provided by Abbott and UK Research and Innovation.